Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY:DGX)

163.80 -0.67 (-0.41%)
Official Closing Price Updated: 7:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Quest Diagnostics

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Quest Diagnostics Delivers Q4 Earnings Beat: The Details
Quest Diagnostics reported fourth-quarter revenue of $2.62 billion, beating analyst estimates of $2.58 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of $2.23... 
Via Benzinga
Quest Diagnostics EPS Tops Predictions
Quest Diagnostics saw robust growth in earnings and revenue, surpassing expectations for Q4 2024. 
Via The Motley Fool
IBM Posts Upbeat Earnings, Joins Oshkosh, Las Vegas Sands, Nokia, Quest Diagnostics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Friday's session: top gainers and losers in the S&P500 index
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Analyst Expectations For Quest Diagnostics's Future
Via Benzinga
How Is The Market Feeling About Quest Diagnostics?
Via Benzinga
The Analyst Landscape: 8 Takes On Quest Diagnostics
Via Benzinga
Earnings Scheduled For January 30, 2025
Via Benzinga
Tesla To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
This Boeing Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. 
Via News Direct
Exposures Product Safety
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
(DGX) - Analyzing Quest Diagnostics's Short Interest
Via Benzinga
How Is The Market Feeling About Quest Diagnostics?
Via Benzinga
Tesla To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Guardant Health Stock Sees RS Rating Jump To 83
On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. 
Via Investor's Business Daily
Navigating Earnings Season: Weather Any Storm
The consequences of hurricanes like Helene and Milton are—typically—quickly shrugged aside by markets as one-off events. That is mostly correct. But not entirely so. For some companies, the revenue and... 
Via Talk Markets
Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare
Trump's second term could bring significant changes to U.S. healthcare, with cuts to ACA subsidies and potential Medicare privatization. 
Via Benzinga
Topics Government
Exposures Political
What Analysts Are Saying About Quest Diagnostics Stock
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
Via Benzinga
Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
LabCorp Q3 2024 EPS beats expectations at $3.50, with 7.4% revenue growth to $3.28B. Adjusted EPS guidance revised due to weather. 
Via Benzinga
Topics Earnings
Exposures Financial
This Snap Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Quest Diagnostics Posts Upbeat Results, Joins GM, Philip Morris And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025
Quest Diagnostics reports strong Q3 with 8.5% sales growth, raises 2024 revenue guidance to $9.80 billion-$9.85 billion, citing acquisitions and new customer wins. 
Via Benzinga
Earnings Preview: Quest Diagnostics
Via Benzinga
Looking Into Quest Diagnostics's Recent Short Interest
Via Benzinga
Decoding 7 Analyst Evaluations For Quest Diagnostics
Via Benzinga
What Analysts Are Saying About Quest Diagnostics Stock
Via Benzinga
Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.